This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spadaro, M. Articles by Forni, G. Search for Related Content PubMed PubMed Citation Articles by Spadaro, M. Articles by Forni, G.

Requirement for IFN-, CD8⁺ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu⁺ Tumors

¹ Molecular Biotechnology Center, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy and ² Agennix, Inc., Houston, Texas

Requests for reprints: Atul Varadhachary, Agennix, Inc., 8 Greenway Plaza, Suite 910, Houston, TX 77046. Phone: 713-552-1091; E-mail: avaradhachary{at}agennix.com.

We have previously shown that talactoferrin-alfa (TLF), a recombinant human lactoferrin, is an immunomodulatory protein that is active against implanted tumors, both as a single agent and in combination with chemotherapy. In this study, we show that talactoferrin is active against autochthonous tumors in a transgenic mouse line, which is more analogous to human cancers, and identify key mechanistic steps involved in the anticancer activity of oral TLF. BALB/c mice transgenic for the rat neu (ErbB2) oncogene (BALB-neuT) treated with oral TLF showed a significant delay in carcinogenesis, with 60% tumor protection relative to vehicle-treated mice at week 21. Oral TLF also showed tumor growth inhibition in wild-type BALB/c mice implanted with neu⁺ mammary adenocarcinoma, with one third displaying a long-lasting or complete response. Oral TLF induces an increase in intestinal mucosal IFN- production and an increase in Peyer's patch cellularity, including expansion of CD8⁺ T lymphocytes and NKT cells, and the enhancement of CD8⁺ T-cell cytotoxicity. In IFN- knockout mice, there is an absence of the TLF-induced Peyer's patch cellularity, no expansion of CD8⁺ T lymphocytes and NKT cells, and loss of TLF anticancer activity. TLF antitumor activity is also lost in mice depleted of CD8⁺ T cells and in CD1 knockout mice, which lack NKT activity. Thus, the inhibition of distant tumors by oral TLF seems to be mediated by an IFN-–dependent enhancement of CD8⁺ T- and NKT cell activity initiated within the intestinal mucosa. [Cancer Res 2007;67(13):6425–32]

This article has been cited by other articles:

				M. Spadaro, C. Caorsi, P. Ceruti, A. Varadhachary, G. Forni, F. Pericle, and M. Giovarelli Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells FASEB J, August 1, 2008; 22(8): 2747 - 2757. [Abstract] [Full Text] [PDF]

				G. de la Rosa, D. Yang, P. Tewary, A. Varadhachary, and J. J. Oppenheim Lactoferrin Acts as an Alarmin to Promote the Recruitment and Activation of APCs and Antigen-Specific Immune Responses J. Immunol., May 15, 2008; 180(10): 6868 - 6876. [Abstract] [Full Text] [PDF]